GW Pharmaceuticals PLC's epilepsy treatment Epidiolex (cannabidiol) has been regarded as highly unusual in that it is now a US FDA-approved drug that is derived from marijuana. Just as unusual, however, is a factor that helped it clear the agency approval hurdle: a review of the safety data led by Office of Drug Evaluation I (ODE-1) Director Ellis Unger.
Reviews of clinical data are almost always conducted by medical officers. The review of the Epidiolex safety data, however, was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?